Non-alcoholic Steatohepatitis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report “Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.
The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.
The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.
Non-alcoholic Steatohepatitis Treatment Market Report Highlights
In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.
The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.
In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.
The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.
A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.
Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:
By Drug Outlook (Revenue, USD Billion; 2020–2034)
Vitamin E and Pioglitazone
Obeticholic Acid (OCA)
Lanifibranor
Semaglutide
Resmetirom
Aramchol
Cenicriviroc
Other Drugs
By Disease Stage Outlook (Revenue, USD Billion; 2020–2034)
NASH Stage F0
NASH Stage F1
NASH Stage F2
NASH Stage F3
NASH Stage F4
By Distribution Channel Outlook (Revenue, USD Billion; 2020–2034)
Hospital Pharmacies
Retail and Specialty Pharmacies
Other Pharmacies
By Regional Outlook (Revenue, USD Billion; 2020–2034)
North America
- US
- Canada
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives Of The Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Non-alcoholic Steatohepatitis Treatment Market Insights
- 4.1. Non-alcoholic Steatohepatitis Treatment Market – Market Snapshot
- 4.2. Non-alcoholic Steatohepatitis Treatment Market Dynamics
- 4.2.1. Drivers And Opportunities
- 4.2.1.1. Rising Aging Population
- 4.2.1.2. Rising Incidence Of Type 2 Diabetes
- 4.2.2. Restraints And Challenges
- 4.2.2.1. High Treatment Costs
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power Of Suppliers (Moderate)
- 4.3.2. Threats Of New Entrants: (Low)
- 4.3.3. Bargaining Power Of Buyers (Moderate)
- 4.3.4. Threat Of Substitute (Moderate)
- 4.3.5. Rivalry Among Existing Firms (High)
- 4.4. Pestel Analysis
- 4.5. Non-alcoholic Steatohepatitis Treatment Market Trends
- 4.6. Value Chain Analysis
- 4.7. Covid-19 Impact Analysis
- 5. Global Non-alcoholic Steatohepatitis Treatment Market, By Drug
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 5.3. Vitamin E And Pioglitazone
- 5.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Vitamin E And Pioglitazone, By Region, 2020-2034 (Usd Billion)
- 5.4. Obeticholic Acid (Oca)
- 5.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Obeticholic Acid (Oca), By Region, 2020-2034 (Usd Billion)
- 5.5. Lanifibranor
- 5.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Lanifibranor, By Region, 2020-2034 (Usd Billion)
- 5.6. Semaglutide
- 5.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Semaglutide, By Region, 2020-2034 (Usd Billion)
- 5.7. Resmetirom
- 5.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Resmetirom, By Region, 2020-2034 (Usd Billion)
- 5.8. Aramchol
- 5.8.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Aramchol, By Region, 2020-2034 (Usd Billion)
- 5.9. Cenicriviroc
- 5.9.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Cenicriviroc, By Region, 2020-2034 (Usd Billion)
- 5.10. Other Drugs
- 5.10.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Other Drugs, By Region, 2020-2034 (Usd Billion)
- 6. Global Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 6.3. Nash Stage F0
- 6.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Nash Stage F0, By Region, 2020-2034 (Usd Billion)
- 6.4. Nash Stage F1
- 6.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Nash Stage F1, By Region, 2020-2034 (Usd Billion)
- 6.5. Nash Stage F2
- 6.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Nash Stage F2, By Region, 2020-2034 (Usd Billion)
- 6.6. Nash Stage F3
- 6.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Nash Stage F3, By Region, 2020-2034 (Usd Billion)
- 6.7. Nash Stage F4
- 6.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Nash Stage F4, By Region, 2020-2034 (Usd Billion)
- 7. Global Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Hospital Pharmacies, By Region, 2020-2034 (Usd Billion)
- 7.4. Retail And Specialty Pharmacies
- 7.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Retail And Specialty Pharmacies, By Region, 2020-2034 (Usd Billion)
- 7.5. Other Pharmacies
- 7.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, By Other Pharmacies, By Region, 2020-2034 (Usd Billion)
- 8. Global Non-alcoholic Steatohepatitis Treatment Market, By Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Non-alcoholic Steatohepatitis Treatment Market Assessment, By Geography, 2020-2034 (Usd Billion)
- 8.3. Non-alcoholic Steatohepatitis Treatment Market – North America
- 8.3.1. North America: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.3.2. North America: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.3.3. North America: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.3.4. Non-alcoholic Steatohepatitis Treatment Market – U.S.
- 8.3.4.1. U.S.: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.3.4.2. U.S.: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.3.4.3. U.S.: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.3.5. Non-alcoholic Steatohepatitis Treatment Market – Canada
- 8.3.5.1. Canada: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.3.5.2. Canada: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.3.5.3. Canada: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4. Non-alcoholic Steatohepatitis Treatment Market – Europe
- 8.4.1. Europe: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.2. Europe: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.3. Europe: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.4. Non-alcoholic Steatohepatitis Treatment Market – Uk
- 8.4.4.1. Uk: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.4.2. Uk: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.4.3. Uk: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.5. Non-alcoholic Steatohepatitis Treatment Market – France
- 8.4.5.1. France: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.5.2. France: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.5.3. France: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.6. Non-alcoholic Steatohepatitis Treatment Market – Germany
- 8.4.6.1. Germany: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.6.2. Germany: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.6.3. Germany: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.7. Non-alcoholic Steatohepatitis Treatment Market – Italy
- 8.4.7.1. Italy: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.7.2. Italy: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.7.3. Italy: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.8. Non-alcoholic Steatohepatitis Treatment Market – Spain
- 8.4.8.1. Spain: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.8.2. Spain: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.8.3. Spain: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.9. Non-alcoholic Steatohepatitis Treatment Market – Netherlands
- 8.4.9.1. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.9.2. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.9.3. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.10. Non-alcoholic Steatohepatitis Treatment Market – Russia
- 8.4.10.1. Russia: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.10.2. Russia: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.10.3. Russia: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.4.11. Non-alcoholic Steatohepatitis Treatment Market – Rest Of Europe
- 8.4.11.1. Rest Of Europe: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.4.11.2. Rest Of Europe: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.4.11.3. Rest Of Europe: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5. Non-alcoholic Steatohepatitis Treatment Market – Asia Pacific
- 8.5.1. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.2. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.3. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.4. Non-alcoholic Steatohepatitis Treatment Market – China
- 8.5.4.1. China: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.4.2. China: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.4.3. China: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.5. Non-alcoholic Steatohepatitis Treatment Market – India
- 8.5.5.1. India: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.5.2. India: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.5.3. India: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.6. Non-alcoholic Steatohepatitis Treatment Market – Malaysia
- 8.5.6.1. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.6.2. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.6.3. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.7. Non-alcoholic Steatohepatitis Treatment Market – Japan
- 8.5.7.1. Japan: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.7.2. Japan: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.7.3. Japan: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.8. Non-alcoholic Steatohepatitis Treatment Market – Indonesia
- 8.5.8.1. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.8.2. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.8.3. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.9. Non-alcoholic Steatohepatitis Treatment Market – South Korea
- 8.5.9.1. South Korea: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.9.2. South Korea: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.9.3. South Korea: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.10. Non-alcoholic Steatohepatitis Treatment Market – Australia
- 8.5.10.1. Australia: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.10.2. Australia: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.10.3. Australia: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.5.11. Non-alcoholic Steatohepatitis Treatment Market – Rest Of Asia Pacific
- 8.5.11.1. Rest Of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.5.11.2. Rest Of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.5.11.3. Rest Of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6. Non-alcoholic Steatohepatitis Treatment Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.2. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.3. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6.4. Non-alcoholic Steatohepatitis Treatment Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.4.2. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.4.3. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6.5. Non-alcoholic Steatohepatitis Treatment Market – Uae
- 8.6.5.1. Uae: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.5.2. Uae: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.5.3. Uae: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6.6. Non-alcoholic Steatohepatitis Treatment Market – Israel
- 8.6.6.1. Israel: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.6.2. Israel: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.6.3. Israel: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6.7. Non-alcoholic Steatohepatitis Treatment Market – South Africa
- 8.6.7.1. South Africa: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.7.2. South Africa: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.7.3. South Africa: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.6.8. Non-alcoholic Steatohepatitis Treatment Market – Rest Of Middle East & Africa
- 8.6.8.1. Rest Of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.6.8.2. Rest Of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.6.8.3. Rest Of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.7. Non-alcoholic Steatohepatitis Treatment Market – Latin America
- 8.7.1. Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.7.2. Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.7.3. Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.7.4. Non-alcoholic Steatohepatitis Treatment Market – Mexico
- 8.7.4.1. Mexico: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.7.4.2. Mexico: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.7.4.3. Mexico: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.7.5. Non-alcoholic Steatohepatitis Treatment Market – Brazil
- 8.7.5.1. Brazil: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.7.5.2. Brazil: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.7.5.3. Brazil: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.7.6. Non-alcoholic Steatohepatitis Treatment Market – Argentina
- 8.7.6.1. Argentina: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.7.6.2. Argentina: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.7.6.3. Argentina: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 8.7.7. Non-alcoholic Steatohepatitis Treatment Market – Rest Of Latin America
- 8.7.7.1. Rest Of Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Drug, 2020-2034 (Usd Billion)
- 8.7.7.2. Rest Of Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Disease Stage, 2020-2034 (Usd Billion)
- 8.7.7.3. Rest Of Latin America: Non-alcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2020-2034 (Usd Billion)
- 9. Competitive Landscape
- 9.1. Expansion And Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Intercept Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Galmed Pharmaceuticals Ltd
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Inventiva
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Abbvie Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Galectin Therapeutics Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Madrigal Pharmaceuticals Inc. (Madrigal)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Ngm Biopharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Novo Nordisk A/S
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. The Bristol-myers Squibb Company
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Gilead Sciences, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook